Intra‑articular Injection Guidelines for Knee Osteoarthritis

First‑Line Injectable Therapy: Corticosteroids

• The American Academy of Orthopaedic Surgeons (AAOS) states that intra‑articular corticosteroid injections are the first‑line injectable option for knee osteoarthritis when conservative measures (e.g., oral NSAIDs, physical therapy, weight control) have failed; this recommendation is based on 19 high‑quality and 6 moderate‑quality studies, with typical symptomatic benefit lasting about 3 months. 1

• Corticosteroids possess the strongest evidence base among all intra‑articular agents for knee osteoarthritis, supported by high‑quality data from the AAOS. 1, 2

• They are particularly indicated for acute pain exacerbations accompanied by joint effusion, as demonstrated in studies published in the Annals of the Rheumatic Diseases. 3, 4

• Expected duration of pain relief and functional improvement after a single injection is limited to weeks‑to‑months, and benefits beyond 3 months should not be anticipated (AAOS high‑quality evidence). 1, 2

Second‑Line Injectable Therapy: Platelet‑Rich Plasma (PRP)

• The AAOS recommends considering PRP only after corticosteroid therapy has failed or in patients with mild‑to‑moderate radiographic disease (Kellgren‑Lawrence grade 1‑2). High‑quality evidence (2 high‑quality and 1 moderate‑quality studies) shows PRP reduces pain and improves function. 1, 2

• PRP demonstrates a poorer treatment response in severe knee osteoarthritis (Kellgren‑Lawrence grade 3‑4), so it should be avoided in that subgroup. (AAOS high‑quality evidence) 1

• Cost and safety concerns for PRP are noted in the AAOS review, reflecting moderate‑quality evidence. 1

Injectable Therapy Not Recommended: Hyaluronic Acid

• The AAOS recommends against routine use of intra‑articular hyaluronic acid for knee osteoarthritis, citing inconsistent evidence across 17 high‑quality and 11 moderate‑quality studies. 1, 2

• The number needed to treat is approximately 17 patients, but no specific patient subset that benefits can be identified (AAOS moderate‑quality evidence). 1, 2

• The American College of Rheumatology (ACR) provides no recommendation for hyaluronic acid because the evidence is equivocal (low‑strength). 5

Clinical Decision Algorithm (AAOS‑Based)

• Acute pain flare with effusion: administer a single intra‑articular corticosteroid injection (20–80 mg methylprednisolone acetate or 5–15 mg triamcinolone hexacetonide). (AAOS high‑quality evidence) 1, 3

• Chronic pain without severe radiographic changes (KL 1‑2): start with corticosteroid injection; if inadequate response after ~3 months, consider PRP. (AAOS high‑quality evidence) 1

• Severe osteoarthritis (KL 3‑4): limit treatment to corticosteroid injection; avoid PRP due to poor efficacy in this subgroup. (AAOS high‑quality evidence) 1

• Routine hyaluronic acid use: should be avoided because of inconsistent efficacy and the AAOS recommendation against it. (AAOS high‑quality evidence) 1, 2

Expected Outcomes and Limitations

All patient descriptors have been generalized to preserve privacy.